197 related articles for article (PubMed ID: 18493247)
1. alpha2A-adrenoceptor antagonism increases insulin secretion and synergistically augments the insulinotropic effect of glibenclamide in mice.
Fagerholm V; Scheinin M; Haaparanta M
Br J Pharmacol; 2008 Jul; 154(6):1287-96. PubMed ID: 18493247
[TBL] [Abstract][Full Text] [Related]
2. Interactions between imidazoline compounds and sulphonylureas in the regulation of insulin secretion.
Mourtada M; Brown CA; Smith SA; Piercy V; Chan SL; Morgan NG
Br J Pharmacol; 1997 Jun; 121(4):799-805. PubMed ID: 9208151
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of the stimulatory effects of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline, RX801080.
Brown CA; Chan SL; Stillings MR; Smith SA; Morgan NG
Br J Pharmacol; 1993 Nov; 110(3):1017-22. PubMed ID: 7905338
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of Glibenclamide Hypoglycaemia in Mice by MK-467, a Peripherally Acting Alpha2-Adrenoceptor Antagonist.
Ruohonen ST; Ranta-Panula V; Bastman S; Chrusciel P; Scheinin M; Streng T
Basic Clin Pharmacol Toxicol; 2015 Dec; 117(6):392-8. PubMed ID: 26132275
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of efaroxan and glibenclamide on plasma glucose and insulin levels in rats.
Berridge TL; Doxey JC; Roach AG
Eur J Pharmacol; 1992 Mar; 213(2):213-8. PubMed ID: 1355734
[TBL] [Abstract][Full Text] [Related]
6. The potential antidiabetic activity of some alpha-2 adrenoceptor antagonists.
Abdel-Zaher AO; Ahmed IT; El-Koussi AD
Pharmacol Res; 2001 Nov; 44(5):397-409. PubMed ID: 11712871
[TBL] [Abstract][Full Text] [Related]
7. Reduced blood glucose levels, increased insulin levels and improved glucose tolerance in alpha2A-adrenoceptor knockout mice.
Savontaus E; Fagerholm V; Rahkonen O; Scheinin M
Eur J Pharmacol; 2008 Jan; 578(2-3):359-64. PubMed ID: 17964569
[TBL] [Abstract][Full Text] [Related]
8. Altered glucose homeostasis in alpha2A-adrenoceptor knockout mice.
Fagerholm V; Grönroos T; Marjamäki P; Viljanen T; Scheinin M; Haaparanta M
Eur J Pharmacol; 2004 Nov; 505(1-3):243-52. PubMed ID: 15556159
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterisation of the thermogenic effect of bupropion.
Liu YL; Connoley IP; Heal DJ; Stock MJ
Eur J Pharmacol; 2004 Sep; 498(1-3):219-25. PubMed ID: 15363998
[TBL] [Abstract][Full Text] [Related]
10. Effects of imidazoline antagonists of alpha 2-adrenoceptors on endogenous adrenaline-induced inhibition of insulin release.
Hiyoshi Y; Miura H; Uemura K; Endo H; Ozawa K; Maeda N; Tamagawa T; Iguchi A
Eur J Pharmacol; 1995 Dec; 294(1):117-23. PubMed ID: 8788423
[TBL] [Abstract][Full Text] [Related]
11. [Ethyl-3H]RS-79948-197 alpha2-adrenoceptor autoradiography validation in alpha2-adrenoceptor knockout mice.
Fagerholm V; Philipp M; Hein L; Scheinin M
Eur J Pharmacol; 2004 Aug; 497(3):301-9. PubMed ID: 15336948
[TBL] [Abstract][Full Text] [Related]
12. Chronic fluoxetine reverses the effects of chronic corticosterone treatment on α
Horrillo I; Ortega JE; Diez-Alarcia R; Urigüen L; Meana JJ
Neuropharmacology; 2019 Nov; 158():107731. PubMed ID: 31376424
[TBL] [Abstract][Full Text] [Related]
13. [3H]RS79948-197 binding to human, rat, guinea pig and pig alpha2A-, alpha2B- and alpha2C-adrenoceptors. Comparison with MK912, RX821002, rauwolscine and yohimbine.
Uhlén S; Dambrova M; Näsman J; Schiöth HB; Gu Y; Wikberg-Matsson A; Wikberg JE
Eur J Pharmacol; 1998 Feb; 343(1):93-101. PubMed ID: 9551719
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of antihyperglycaemic action of efaroxan in mice: time for reappraisal of α2A-adrenergic antagonism in the treatment of type 2 diabetes?
Lehner Z; Stadlbauer K; Adorjan I; Rustenbeck I; Belz M; Fenzl A; de Cillia VA; Gruber D; Bauer L; Frobel K; Brunmair B; Luger A; Fürnsinn C
Diabetologia; 2012 Nov; 55(11):3071-82. PubMed ID: 22898767
[TBL] [Abstract][Full Text] [Related]
15. Alpha2-adrenoceptor-mediated inhibition of cultured sympathetic neurons: changes in alpha2A/D-adrenoceptor-deficient mice.
Trendelenburg AU; Nörenberg W; Hein L; Meyer A; Starke K
Naunyn Schmiedebergs Arch Pharmacol; 2001 Jan; 363(1):110-9. PubMed ID: 11191829
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the receptor involved in the central hypotensive effect of rilmenidine and moxonidine.
Bock C; Niederhoffer N; Szabo B
Naunyn Schmiedebergs Arch Pharmacol; 1999 Apr; 359(4):262-71. PubMed ID: 10344524
[TBL] [Abstract][Full Text] [Related]
17. The pharmacology of RS-15385-197, a potent and selective alpha 2-adrenoceptor antagonist.
Brown CM; MacKinnon AC; Redfern WS; Hicks PE; Kilpatrick AT; Small C; Ramcharan M; Clague RU; Clark RD; MacFarlane CB
Br J Pharmacol; 1993 Feb; 108(2):516-25. PubMed ID: 8095420
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of the hypoglycemic effects of the alpha2-adrenoceptor antagonists SL84.0418 and deriglidole.
Guillot E; Coste A; Eon MT; Angel I
Life Sci; 1998; 62(9):839-52. PubMed ID: 9496702
[TBL] [Abstract][Full Text] [Related]
19. A study of presynaptic alpha2-autoreceptors in alpha2A/D-, alpha2B- and alpha2C-adrenoceptor-deficient mice.
Trendelenburg AU; Klebroff W; Hein L; Starke K
Naunyn Schmiedebergs Arch Pharmacol; 2001 Aug; 364(2):117-30. PubMed ID: 11534851
[TBL] [Abstract][Full Text] [Related]
20. Chronic sympathetic innervation of islets in transgenic mice results in differential desensitization of alpha-adrenergic inhibition of insulin secretion.
Grodsky GM; Ma YH; Edwards RH
Adv Exp Med Biol; 1997; 426():129-38. PubMed ID: 9544265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
